|
AU1941501A
(en)
*
|
1999-11-30 |
2001-06-12 |
Parker Hughes Institute |
Syk localized at centrosome
|
|
TWI329105B
(en)
|
2002-02-01 |
2010-08-21 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidinediamine compounds and their uses
|
|
US20040171062A1
(en)
*
|
2002-02-28 |
2004-09-02 |
Plexxikon, Inc. |
Methods for the design of molecular scaffolds and ligands
|
|
HRP20050089B1
(hr)
|
2002-07-29 |
2015-06-19 |
Rigel Pharmaceuticals |
Upotreba 2,4 pirimidindiaminskog spoja za proizvodnju lijeka za lijeäśenje ili sprjeäśavanje autoimunosne bolesti
|
|
AU2003272548A1
(en)
*
|
2002-09-16 |
2004-04-30 |
Plexxikon, Inc. |
Crystal structure of pim-1 kinase
|
|
US20050282814A1
(en)
*
|
2002-10-03 |
2005-12-22 |
Targegen, Inc. |
Vasculostatic agents and methods of use thereof
|
|
US7456190B2
(en)
*
|
2003-03-13 |
2008-11-25 |
Vertex Pharmaceuticals Incorporated |
Compositions useful as protein kinase inhibitors
|
|
US20050014753A1
(en)
*
|
2003-04-04 |
2005-01-20 |
Irm Llc |
Novel compounds and compositions as protein kinase inhibitors
|
|
WO2005003101A2
(en)
*
|
2003-07-02 |
2005-01-13 |
Biofocus Discovery Limited |
Pyrazine and pyridine derivatives as rho kinase inhibitors
|
|
EP1648875A1
(en)
|
2003-07-30 |
2006-04-26 |
Cyclacel Limited |
2-aminophenyl-4-phenylpyrimidines as kinase inhibitors
|
|
WO2005012294A1
(en)
|
2003-07-30 |
2005-02-10 |
Rigel Pharmaceuticals, Inc. |
2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
|
|
EP1694686A1
(en)
*
|
2003-12-19 |
2006-08-30 |
Takeda San Diego, Inc. |
Kinase inhibitors
|
|
EP2543376A1
(en)
*
|
2004-04-08 |
2013-01-09 |
Targegen, Inc. |
Benzotriazine inhibitors of kinases
|
|
US20050250829A1
(en)
*
|
2004-04-23 |
2005-11-10 |
Takeda San Diego, Inc. |
Kinase inhibitors
|
|
WO2005105780A2
(en)
*
|
2004-04-28 |
2005-11-10 |
Vertex Pharmaceuticals Incorporated |
Compositions useful as inhibitors of rock and other protein kinases
|
|
UA84930C2
(ru)
*
|
2004-05-14 |
2008-12-10 |
Вертекс Фармасьютикалс Инкорпорейтед |
Пиррольные соединения как ингибиторы протеинкиназ erk, их синтез и соответствующие промежуточные соединения
|
|
WO2006023931A2
(en)
*
|
2004-08-18 |
2006-03-02 |
Takeda San Diego, Inc. |
Kinase inhibitors
|
|
US7652051B2
(en)
|
2004-08-25 |
2010-01-26 |
Targegen, Inc. |
Heterocyclic compounds and methods of use
|
|
US8771754B2
(en)
*
|
2004-09-17 |
2014-07-08 |
Vanderbilt University |
Use of GSK3 inhibitors in combination with radiation therapies
|
|
EP1812439B2
(en)
*
|
2004-10-15 |
2017-12-06 |
Takeda Pharmaceutical Company Limited |
Kinase inhibitors
|
|
US7968574B2
(en)
*
|
2004-12-28 |
2011-06-28 |
Kinex Pharmaceuticals, Llc |
Biaryl compositions and methods for modulating a kinase cascade
|
|
AU2006206458B2
(en)
|
2005-01-19 |
2012-10-25 |
Rigel Pharmaceuticals, Inc. |
Prodrugs of 2,4-pyrimidinediamine compounds and their uses
|
|
BRPI0607062A2
(pt)
|
2005-02-28 |
2009-08-04 |
Japan Tobacco Inc |
composto de aminopiridina com atividade inibidora de syk, composição farmacêutica e agente terapêutico compreendendo os mesmos
|
|
AU2006254825A1
(en)
*
|
2005-06-08 |
2006-12-14 |
Targegen, Inc. |
Methods and compositions for the treatment of ocular disorders
|
|
BRPI0610876B8
(pt)
|
2005-06-08 |
2021-05-25 |
Rigel Pharmaceuticals Inc |
composto, formulação farmacêutica, e métodos de inibir uma atividade de uma jak cinase, e de inibir uma cascata de transdução de sinal em que jak3 cinase desempenha um papel
|
|
US20070203161A1
(en)
|
2006-02-24 |
2007-08-30 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
|
US7825244B2
(en)
|
2005-06-10 |
2010-11-02 |
Janssen Pharmaceutica Nv |
Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis
|
|
US20060281788A1
(en)
|
2005-06-10 |
2006-12-14 |
Baumann Christian A |
Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
|
|
US8071768B2
(en)
|
2005-06-10 |
2011-12-06 |
Janssen Pharmaceutica, N.V. |
Alkylquinoline and alkylquinazoline kinase modulators
|
|
JP2008543855A
(ja)
|
2005-06-13 |
2008-12-04 |
ライジェル ファーマシューティカルズ， インコーポレイテッド |
変形性骨疾患を処置するための方法および組成物
|
|
ATE352714T1
(de)
*
|
2005-06-17 |
2007-02-15 |
Magneti Marelli Powertrain Spa |
Brennstoffeinspritzventil
|
|
WO2007009083A2
(en)
*
|
2005-07-12 |
2007-01-18 |
Acadia Pharmaceuticals Inc. |
Compounds with activity at retinoic acid receptors
|
|
US8211919B2
(en)
*
|
2005-09-02 |
2012-07-03 |
Astellas Pharma Inc. |
Amide derivatives as rock inhibitors
|
|
US7512864B2
(en)
*
|
2005-09-30 |
2009-03-31 |
Josef Zeevi |
System and method of accessing non-volatile computer memory
|
|
US8119655B2
(en)
*
|
2005-10-07 |
2012-02-21 |
Takeda Pharmaceutical Company Limited |
Kinase inhibitors
|
|
AU2006304897B2
(en)
|
2005-10-18 |
2012-07-12 |
Janssen Pharmaceutica N.V. |
Method of inhibiting FLT3 kinase
|
|
US8133900B2
(en)
*
|
2005-11-01 |
2012-03-13 |
Targegen, Inc. |
Use of bi-aryl meta-pyrimidine inhibitors of kinases
|
|
JP5191391B2
(ja)
|
2005-11-01 |
2013-05-08 |
ターゲジェン インコーポレーティッド |
キナーゼのビ−アリールメタ−ピリミジン阻害剤
|
|
US8604042B2
(en)
*
|
2005-11-01 |
2013-12-10 |
Targegen, Inc. |
Bi-aryl meta-pyrimidine inhibitors of kinases
|
|
WO2007056075A2
(en)
*
|
2005-11-02 |
2007-05-18 |
Targegen, Inc. |
Six membered heteroaromatic inhibitors targeting resistant kinase mutations
|
|
KR20080110998A
(ko)
|
2006-01-30 |
2008-12-22 |
엑셀리시스, 인코포레이티드 |
Ｊａｋ２ 조절자로서 ４아릴２아미노피리미딘 또는 4아릴２아미노알킬피리미딘 및 이들을 포함하는 약제학적 조성물
|
|
ES2622493T3
(es)
|
2006-02-24 |
2017-07-06 |
Rigel Pharmaceuticals, Inc. |
Composiciones y métodos para la inhibición de la ruta de JAK
|
|
US7834178B2
(en)
*
|
2006-03-01 |
2010-11-16 |
Bristol-Myers Squibb Company |
Triazine 11-beta hydroxysteroid dehydrogenase type 1 inhibitors
|
|
US8133867B2
(en)
|
2006-03-20 |
2012-03-13 |
Seikagaku Corporation |
Method for treating rheumatoid arthritis with an antibody that binds to a hepatocyte growth factor receptor
|
|
MX2008012479A
(es)
*
|
2006-03-29 |
2009-08-13 |
Velacor Therapeutics Pty Ltd |
Tratamiento de enfermedades neurodegenerativas.
|
|
WO2007124319A1
(en)
|
2006-04-20 |
2007-11-01 |
Janssen Pharmaceutica N.V. |
Inhibitors of c-fms kinase
|
|
PL2021335T3
(pl)
|
2006-04-20 |
2011-10-31 |
Janssen Pharmaceutica Nv |
Związki heterocykliczne jako inhibitory kinazy C-FMS
|
|
US8697716B2
(en)
|
2006-04-20 |
2014-04-15 |
Janssen Pharmaceutica Nv |
Method of inhibiting C-KIT kinase
|
|
JP5564251B2
(ja)
|
2006-06-29 |
2014-07-30 |
キネックス ファーマシューティカルズ， エルエルシー |
キナーゼカスケードを調節するためのビアリール組成物および方法
|
|
WO2008008234A1
(en)
|
2006-07-07 |
2008-01-17 |
Targegen, Inc. |
2-amino-5-substituted pyrimidine inhibitors
|
|
EP2223925A1
(en)
*
|
2006-10-09 |
2010-09-01 |
Takeda Pharmaceutical Company Limited |
Kinase inhibitors
|
|
SG158147A1
(en)
|
2006-10-09 |
2010-01-29 |
Takeda Pharmaceutical |
Kinase inhibitors
|
|
US20080153822A1
(en)
*
|
2006-11-30 |
2008-06-26 |
Martin Augustin |
Methods of treating pain
|
|
US7935697B2
(en)
|
2006-12-28 |
2011-05-03 |
Kinex Pharmaceuticals, Llc |
Compositions for modulating a kinase cascade and methods of use thereof
|
|
KR101566840B1
(ko)
|
2007-03-12 |
2015-11-06 |
와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 |
페닐 아미노 피리미딘 화합물 및 이의 용도
|
|
WO2008119109A1
(en)
|
2007-03-29 |
2008-10-09 |
Velacor Therapeutics Pty Ltd |
Treatment of neurological disorders
|
|
CN101903349B
(zh)
*
|
2007-08-27 |
2014-01-08 |
Abbvie德国有限责任两合公司 |
4-(4-吡啶基)-苯甲酰胺及其作为rock活性调节剂的应用
|
|
JO3240B1
(ar)
|
2007-10-17 |
2018-03-08 |
Janssen Pharmaceutica Nv |
c-fms مثبطات كيناز
|
|
HUE030912T2
(en)
|
2008-02-15 |
2017-06-28 |
Rigel Pharmaceuticals Inc |
Pyrimidine-2-amine compounds and their use as inhibitors of yak kinases
|
|
WO2009117387A2
(en)
*
|
2008-03-17 |
2009-09-24 |
The Trustees Of Columbia University In The City Of New York |
Methods to treat neurodegenerative conditions or diseases by targeting components of a pten signaling pathway
|
|
US8063058B2
(en)
|
2008-04-16 |
2011-11-22 |
Portola Pharmaceuticals, Inc. |
Inhibitors of syk and JAK protein kinases
|
|
US8138339B2
(en)
|
2008-04-16 |
2012-03-20 |
Portola Pharmaceuticals, Inc. |
Inhibitors of protein kinases
|
|
AU2009238590A1
(en)
|
2008-04-22 |
2009-10-29 |
Portola Pharmaceuticals, Inc. |
Inhibitors of protein kinases
|
|
JP2011523551A
(ja)
*
|
2008-05-15 |
2011-08-18 |
ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル |
血管形成の調節の新規ターゲット
|
|
WO2009154697A2
(en)
|
2008-05-28 |
2009-12-23 |
Massachusetts Institute Of Technology |
Disc-1 pathway activators in the control of neurogenesis
|
|
US8513242B2
(en)
|
2008-12-12 |
2013-08-20 |
Cystic Fibrosis Foundation Therapeutics, Inc. |
Pyrimidine compounds and methods of making and using same
|
|
MX2011012343A
(es)
*
|
2009-05-19 |
2011-12-14 |
Dow Agrosciences Llc |
Compuestos y metodos para controlar hongos.
|
|
NZ601267A
(en)
|
2009-12-23 |
2014-03-28 |
Takeda Pharmaceutical |
Fused heteroaromatic pyrrolidinones as syk inhibitors
|
|
HUE045270T2
(hu)
|
2010-01-05 |
2019-12-30 |
Inst Nat Sante Rech Med |
FLT3 receptor anatgonisták fájdalom rendellenességek kezelésére
|
|
ES2539170T3
(es)
|
2010-01-12 |
2015-06-26 |
Ab Science |
Inhibidores de quinasas de oxazol
|
|
US8334292B1
(en)
|
2010-06-14 |
2012-12-18 |
Cystic Fibrosis Foundation Therapeutics, Inc. |
Pyrimidine compounds and methods of making and using same
|
|
RU2607033C2
(ru)
*
|
2010-09-28 |
2017-01-10 |
Ноно Инк. |
Пептиды nd2 и способы лечения неврологического заболевания
|
|
EP2975027A1
(en)
|
2010-11-01 |
2016-01-20 |
Portola Pharmaceuticals, Inc. |
Nicotinamides as jak kinase modulators
|
|
AU2010363329A1
(en)
|
2010-11-07 |
2013-05-09 |
Targegen, Inc. |
Compositions and methods for treating myelofibrosis
|
|
JP2014500254A
(ja)
*
|
2010-11-09 |
2014-01-09 |
セルゾーム リミティッド |
Ｔｙｋ２阻害剤としてのピリジン化合物およびそのアザ類似体
|
|
EP3502236B1
(en)
|
2011-02-18 |
2023-08-23 |
The Scripps Research Institute |
Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate
|
|
EP2723739B1
(en)
|
2011-06-22 |
2016-08-24 |
Takeda Pharmaceutical Company Limited |
Substituted 6-aza-isoindolin-1-one derivatives
|
|
DE102011112978A1
(de)
*
|
2011-09-09 |
2013-03-14 |
Merck Patent Gmbh |
Benzonitrilderivate
|
|
MX363551B
(es)
|
2011-11-23 |
2019-03-27 |
Portola Pharmaceuticals Inc Star |
Compuestos derivados de pirazina como inhibidores de cinasa.
|
|
MX371331B
(es)
|
2012-04-24 |
2020-01-27 |
Vertex Pharma |
Inhibidores de la proteina cinasa dependiente de acido desoxirribonucleico(adn-pk).
|
|
US8809359B2
(en)
|
2012-06-29 |
2014-08-19 |
Ym Biosciences Australia Pty Ltd |
Phenyl amino pyrimidine bicyclic compounds and uses thereof
|
|
CN104870454B
(zh)
|
2012-08-07 |
2020-03-03 |
詹森药业有限公司 |
用于制备杂环酯衍生物的方法
|
|
ES2658773T3
(es)
|
2012-08-07 |
2018-03-12 |
Janssen Pharmaceutica N.V. |
Procedimiento de sulfonilación usando fluoruro de nonafluorobutanosulfonilo
|
|
CN102827085A
(zh)
*
|
2012-09-17 |
2012-12-19 |
符爱清 |
2,4,5-三氯嘧啶化合物的制备方法
|
|
KR101738063B1
(ko)
|
2012-09-21 |
2017-05-19 |
아로그 파마슈티칼스, 인코퍼레이티드 |
구조적으로 활성인 인산화된 ｆｌｔ３ 키나제의 억제 방법
|
|
WO2014058921A2
(en)
|
2012-10-08 |
2014-04-17 |
Portola Pharmaceuticals, Inc. |
Substituted pyrimidinyl kinase inhibitors
|
|
BR112015016282A2
(en)
|
2013-01-07 |
2017-07-11 |
Arog Pharmaceuticals, Inc. |
crenolanib for treatment of mutated flt3 proliferative disorders
|
|
ME03336B
(me)
|
2013-03-12 |
2019-10-20 |
Vertex Pharma |
Inhibitori dnk-pk
|
|
JP6408569B2
(ja)
|
2013-10-17 |
2018-10-17 |
バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ |
Ｄｎａ−ｐｋ阻害剤としての（ｓ）−ｎ−メチル−８−（１−（（２’−メチル−［４，５’−ビピリミジン］−６−イル）アミノ）プロパン−２−イル）キノリン−４−カルボキサミドおよびその重水素化誘導体の共結晶
|
|
US10463658B2
(en)
|
2013-10-25 |
2019-11-05 |
Videra Pharmaceuticals, Llc |
Method of inhibiting FLT3 kinase
|
|
AP2016009099A0
(en)
|
2013-11-01 |
2016-03-31 |
Novartis Ag |
Aminoheteroaryl benzamides as kinase inhibitors
|
|
CA2932353A1
(en)
|
2013-12-13 |
2015-06-18 |
Steven P. Treon |
Methods to treat lymphoplasmacytic lymphoma
|
|
EP3079683A4
(en)
|
2013-12-13 |
2017-12-20 |
Dana-Farber Cancer Institute, Inc. |
Methods to treat lymphoplasmacytic lymphoma
|
|
TWI729644B
(zh)
|
2014-06-12 |
2021-06-01 |
美商西爾拉癌症醫學公司 |
N-(氰基甲基)-4-(2-(4-𠰌啉基苯基胺基)嘧啶-4-基)苯甲醯胺
|
|
BR112017002001B1
(pt)
|
2014-07-31 |
2022-10-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Compostos e composição farmacêutica
|
|
CN107073069B
(zh)
*
|
2014-08-18 |
2022-03-08 |
康奈尔大学 |
作为人免疫蛋白酶体的抑制剂的二肽模拟物
|
|
EP3715346B1
(en)
|
2014-10-22 |
2024-01-03 |
Dana-Farber Cancer Institute, Inc. |
Thiazolyl-containing compounds for treating proliferative diseases
|
|
EP3255042B1
(en)
|
2015-02-04 |
2020-12-30 |
Beyondbio Inc. |
Heterocyclic compound and pharmaceutical composition comprising same
|
|
EP3319968A1
(en)
|
2015-07-06 |
2018-05-16 |
Rodin Therapeutics, Inc. |
Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
|
|
WO2017007756A1
(en)
|
2015-07-06 |
2017-01-12 |
Rodin Therapeutics, Inc |
Hetero-halo inhibitors of histone deacetylase
|
|
EP3254698A1
(en)
|
2016-06-08 |
2017-12-13 |
Universite De Montpellier |
Flt3 receptor inhibitor at low dosage for the treatment of neuropathic pain
|
|
EP3518931A4
(en)
|
2016-09-27 |
2020-05-13 |
Vertex Pharmaceuticals Incorporated |
METHOD FOR TREATING CANCER WITH A COMBINATION OF DNA-DAMAGING SUBSTANCES AND DNA-PK INHIBITORS
|
|
US12534764B2
(en)
|
2016-11-02 |
2026-01-27 |
Arog Pharmaceuticals, Inc. |
Crenolanib for treating FLT3 mutated proliferative disorders associated mutations
|
|
EA201991078A1
(ru)
|
2016-11-02 |
2019-11-29 |
|
Креноланиб для лечения пролиферативных расстройств, связанных с мутацией flt3
|
|
HUE057849T2
(hu)
|
2017-01-11 |
2022-06-28 |
Alkermes Inc |
Hiszton deacetiláz biciklusos gátlói
|
|
CA3057969A1
(en)
|
2017-05-02 |
2018-11-08 |
Novartis Ag |
Combination therapy
|
|
JP2020519665A
(ja)
|
2017-05-17 |
2020-07-02 |
アンセルム（アンスティテュト ナショナル ド ラ サンテ エ ド ラ ルシェルシュ メディカル） |
オピオイドによる痛みの処置を改善する為のｆｌｔ３阻害剤
|
|
US11331313B2
(en)
|
2017-05-22 |
2022-05-17 |
Whitehead Institute For Biomedical Research |
KCC2 expression enhancing compounds and uses thereof
|
|
LT3664802T
(lt)
|
2017-08-07 |
2022-06-27 |
Alkermes, Inc. |
Bicikliniai histonų deacetilazės inhibitoriai
|
|
WO2019057649A1
(en)
|
2017-09-19 |
2019-03-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA
|
|
CN110833551B
(zh)
*
|
2018-08-15 |
2023-03-24 |
广西梧州制药（集团）股份有限公司 |
吡唑并嘧啶衍生物在治疗急性胰腺炎的用途
|
|
JP7631193B2
(ja)
|
2018-10-22 |
2025-02-18 |
アルミス インコーポレイテッド |
Ｔｙｋ２阻害剤およびその使用
|
|
US12208098B2
(en)
|
2018-11-26 |
2025-01-28 |
Gachon University Of Industry-Academic Cooperation Foundation |
4-carbonylamino-4-phenylpyrimidine compound or pharmaceutically acceptable salt thereof
|
|
EP3920885A1
(en)
|
2019-02-08 |
2021-12-15 |
Frequency Therapeutics, Inc. |
Valproic acid compounds and wnt agonists for treating ear disorders
|
|
EP3969449B1
(en)
|
2019-05-13 |
2025-02-12 |
Novartis AG |
New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer
|
|
WO2022019998A1
(en)
|
2020-07-20 |
2022-01-27 |
Arog Pharmaceuticals, Inc. |
Crystal forms of crenolanib and methods of use thereof
|
|
US11969420B2
(en)
|
2020-10-30 |
2024-04-30 |
Arog Pharmaceuticals, Inc. |
Combination therapy of crenolanib and apoptosis pathway agents for the treatment of proliferative disorders
|
|
WO2022090547A1
(en)
|
2020-10-30 |
2022-05-05 |
Dsm Ip Assets B.V. |
Production of carotenoids by fermentation
|
|
CN115677595B
(zh)
*
|
2022-10-26 |
2024-06-14 |
江苏睿实生物科技有限公司 |
一种2,4,5-三氯嘧啶的制备方法
|
|
CN116751191B
(zh)
*
|
2023-05-19 |
2025-09-16 |
凌科药业(杭州)有限公司 |
一种吡唑基-氨基-嘧啶基衍生物的晶型、制备方法及应用
|
|
KR20250075302A
(ko)
*
|
2023-11-21 |
2025-05-28 |
(주)신테카바이오 |
크레놀라닙 또는 이의 약학적으로 허용 가능한 염을 포함하는 아토피 피부염의 예방 또는 치료용 조성물
|
|
WO2025221087A1
(ko)
*
|
2024-04-19 |
2025-10-23 |
인제대학교 산학협력단 |
피디케이원 조절제 화합물 및 그를 포함하는 조성물
|
|
WO2026024674A1
(en)
|
2024-07-22 |
2026-01-29 |
Genesis Therapeutics, Inc. |
Methods of treating skp2-associated cancers
|